Moving Forward
These adalimumab biosimilars are only the first step toward expansion of such agents. The FDA is currently reviewing two ustekinumab biosimilars, with decisions likely to come in fall 2023, with more under development. The FDA is also reviewing a biosimilar for tocilizumab, with a decision expected later this year. Other biosimilar products, such as for secukinumab, are also under development.5
Hopefully the transition will be relatively smooth for patients and providers. “I’m not as concerned about which biosimilars I’m going to be asked to use,” says Dr. Helfgott. “I’m more concerned about the patients’ perspective, whether they are going to have the same copayments and access to the product and so forth. As long as that isn’t made more challenging, I think it should be okay.”
On Sept. 12, the ACR launched a patient education campaign, Biosimilars & You: A Guide for Patients with Rheumatic Disease as part of Rheumatic Disease Awareness Month (RDAM). Review and download the materials here.
Ruth Jessen Hickman, MD, is a graduate of the Indiana University School of Medicine. She is a freelance medical and science writer living in Bloomington, Ind.
References
- Jeremias S. First round of adalimumab biosimilars launches in July. American Journal of Managed Care. The Center for Biosimilars. 2023 Jul 2.
- American College of Rheumatology Position Statement: Biosimilars. Committee on Rheumatologic Care. [n.d.]
- Jeremias S. US welcomes first adalimumab biosimilar, Amjevita. American Journal of Managed Care. The Center for Biosimilars. 2023 Jan 31.
- Breaking down the hottest topic in pharmacy—Humira biosimilars. Goodroot. 2023.
- Joszt L. New biosimilars poised to make waves. Drug Topics. 2023 Feb 27.
- Contreras B. The future of savings in Humira biosimilars are [sic.] low. Managed Healthcare Executive. 2023 Jan 29.
- Gibofsky A, Jacobson G, Franklin A, et al. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars. J Manag Care Spec Pharm. 2023 Apr;29(4):343–349.
